277 related articles for article (PubMed ID: 30348619)
21. EVALUATION OF 5-FLUOROURACIL-INDUCED CARDIOTOXICITY: ROLE OF CARDIAC BIOMARKERS.
Moghaddam Z; Rostami M; Zeraatchi A; Abadi H; Karamitanha F; Amirmoghaddami H
Exp Oncol; 2022 May; 44(1):60-66. PubMed ID: 35548958
[TBL] [Abstract][Full Text] [Related]
22. Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up.
Meydan N; Kundak I; Yavuzsen T; Oztop I; Barutca S; Yilmaz U; Alakavuklar MN
Jpn J Clin Oncol; 2005 May; 35(5):265-70. PubMed ID: 15855175
[TBL] [Abstract][Full Text] [Related]
23. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
24. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
25. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
Deboever G; Hiltrop N; Cool M; Lambrecht G
Clin Colorectal Cancer; 2013 Mar; 12(1):8-14. PubMed ID: 23102544
[TBL] [Abstract][Full Text] [Related]
26. Alternative Treatment Options in Patients with Colorectal Cancer Who Encounter Fluoropyrimidine-Induced Cardiotoxicity.
Saif MW
Onco Targets Ther; 2020; 13():10197-10206. PubMed ID: 33116601
[TBL] [Abstract][Full Text] [Related]
27. [Fluoropyrimidines cardiac toxicity: 5-fluorouracil, capecitabine, compound S-1 and trifluridine/tipiracil].
Vaflard P; Ederhy S; Torregrosa C; André T; Cohen R; Lopez-Trabada D
Bull Cancer; 2018; 105(7-8):707-719. PubMed ID: 29960638
[TBL] [Abstract][Full Text] [Related]
28. Cardiotoxicity and capecitabine: a case report.
Singer M
Clin J Oncol Nurs; 2003; 7(1):72-5. PubMed ID: 12629938
[TBL] [Abstract][Full Text] [Related]
29. Comparison of 5-FU-based and Capecitabine-based Neoadjuvant Chemoradiotherapy in Patients With Rectal Cancer: A Meta-analysis.
Zou XC; Wang QW; Zhang JM
Clin Colorectal Cancer; 2017 Sep; 16(3):e123-e139. PubMed ID: 28284574
[TBL] [Abstract][Full Text] [Related]
30. Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment.
Molteni LP; Rampinelli I; Cergnul M; Scaglietti U; Paino AM; Noonan DM; Bucci EO; Gottardi O; Albini A
Breast J; 2010; 16 Suppl 1():S45-8. PubMed ID: 21050310
[TBL] [Abstract][Full Text] [Related]
31. Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results.
Benson AB
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):28-34. PubMed ID: 9830622
[TBL] [Abstract][Full Text] [Related]
32. Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge.
Vater LB; Lefebvre B; Turk A; Clasen SC
Curr Oncol Rep; 2022 Jul; 24(7):943-950. PubMed ID: 35347593
[TBL] [Abstract][Full Text] [Related]
33. Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.
Wu Z; Deng Y
Curr Treat Options Oncol; 2018 Nov; 19(12):77. PubMed ID: 30483908
[TBL] [Abstract][Full Text] [Related]
34. Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy.
Karakulak UN; Aladağ E; Maharjan N; Övünç K
Turk Kardiyol Dern Ars; 2016 Jan; 44(1):71-4. PubMed ID: 26875134
[TBL] [Abstract][Full Text] [Related]
35. Cardiotoxicity of the antiproliferative compound fluorouracil.
Becker K; Erckenbrecht JF; Häussinger D; Frieling T
Drugs; 1999 Apr; 57(4):475-84. PubMed ID: 10235688
[TBL] [Abstract][Full Text] [Related]
36. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Carrato A; Gallego-Plazas J; Guillén-Ponce C
Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
[TBL] [Abstract][Full Text] [Related]
37. An unusual case of acute myopericarditis after the first dose of capecitabine: Need for new cardioprotective strategies and risk stratification.
Meter M; Gavran I; Bajo D; Duplancic D
Int J Clin Pharmacol Ther; 2021 Dec; 59(12):775-779. PubMed ID: 34503643
[TBL] [Abstract][Full Text] [Related]
38. A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center.
Khan MA; Masood N; Husain N; Ahmad B; Aziz T; Naeem A
J Pak Med Assoc; 2012 May; 62(5):430-4. PubMed ID: 22755303
[TBL] [Abstract][Full Text] [Related]
39. Oral fluoropyrimidines: a closer look at their toxicities.
Macdonald JS
Am J Clin Oncol; 1999 Oct; 22(5):475-80. PubMed ID: 10521062
[TBL] [Abstract][Full Text] [Related]
40. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil.
Frickhofen N; Beck FJ; Jung B; Fuhr HG; Andrasch H; Sigmund M
Ann Oncol; 2002 May; 13(5):797-801. PubMed ID: 12075751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
